{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:03:15Z","timestamp":1790661795511,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,7]],"date-time":"2017-10-07T00:00:00Z","timestamp":1507334400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100011019","name":"National Research, Development and Innovation Office","doi-asserted-by":"crossref","award":["K105132"],"award-info":[{"award-number":["K105132"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011019","name":"National Research, Development and Innovation Office","doi-asserted-by":"crossref","award":["K116295"],"award-info":[{"award-number":["K116295"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["GINOP_2.3.2-15-2016-00020"],"award-info":[{"award-number":["GINOP_2.3.2-15-2016-00020"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00262-017-2072-1","type":"journal-article","created":{"date-parts":[[2017,10,7]],"date-time":"2017-10-07T10:54:21Z","timestamp":1507373661000},"page":"141-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy"],"prefix":"10.1007","volume":"67","author":[{"given":"T\u00edmea","family":"Balatoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Mohos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00edmea","family":"Sebesty\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Liszkay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Ol\u00e1h","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Lengyel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Emri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Gaudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9304-8473","authenticated-orcid":false,"given":"Andrea","family":"Lad\u00e1nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,7]]},"reference":[{"issue":"Suppl 3","key":"2072_CR1","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S0959-8049(16)30325-2","volume":"51","author":"A Lad\u00e1nyi","year":"2015","unstructured":"Lad\u00e1nyi A, Sebesty\u00e9n T, Balatoni T, Varga A, Ol\u00e1h J, Liszkay G (2015) Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab. Eur J Cancer 51(Suppl 3):S111\u2013112 (Abstract)","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"2072_CR2","first-page":"8","volume":"15","author":"T Balatoni","year":"2017","unstructured":"Balatoni T, Mohos A, Sebesty\u00e9n T, Varga A, Ol\u00e1h J, Lengyel Z, Emri G, Liszkay G, Lad\u00e1nyi A (2017) Tumor-infiltrating immune cells as potential predictive markers of response to treatment and survival in metastatic melanoma patients receiving ipilimumab. J Transl Med 15(Suppl 1):8 (O7, Abstract)","journal-title":"J Transl Med"},{"key":"2072_CR3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264","journal-title":"Nat Rev Cancer"},{"key":"2072_CR4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"2072_CR5","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O\u2019Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ et al (2011) Ipilimumab plus dacarbazine for previously untreated melanoma. N Engl J Med 364:2517\u20132526","journal-title":"N Engl J Med"},{"key":"2072_CR6","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889\u20131894","journal-title":"J Clin Oncol"},{"key":"2072_CR7","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-12-3243","volume":"19","author":"Y Feng","year":"2013","unstructured":"Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS (2013) Exposure\u2013response relationship of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 19:3977\u20133986","journal-title":"Clin Cancer Res"},{"key":"2072_CR8","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-12-2982","volume":"19","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD (2013) Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 19:1009\u20131020","journal-title":"Clin Cancer Res"},{"key":"2072_CR9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/intimm\/dxu076","volume":"27","author":"CU Blank","year":"2014","unstructured":"Blank CU, Enk A (2014) Therapeutic use of anti-CTLA-4 antibodies. Int Immunol 27:3\u201310","journal-title":"Int Immunol"},{"key":"2072_CR10","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1053\/j.seminoncol.2015.02.016","volume":"42","author":"B Weide","year":"2015","unstructured":"Weide B, Di Giacomo AM, Fonsatti E, Zitvogel L (2015) Immunologic correlates in the course of treatment with immunomodulating antibodies. Semin Oncol 42:448\u2013458","journal-title":"Semin Oncol"},{"key":"2072_CR11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11912-016-0509-x","volume":"18","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Postow MA (2016) Emerging tissue and blood-based biomarkers that may predict response to immune checkpoint inhibition. Curr Oncol Rep 18:21","journal-title":"Curr Oncol Rep"},{"key":"2072_CR12","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","volume":"22","author":"A Martens","year":"2016","unstructured":"Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M et al (2016) Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 22:2908\u20132918","journal-title":"Clin Cancer Res"},{"key":"2072_CR13","doi-asserted-by":"crossref","first-page":"16723","DOI":"10.1073\/pnas.1110814108","volume":"108","author":"J Yuan","year":"2011","unstructured":"Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Allison JP, Old LJ, Wolchok JD, Gnjatic S (2011) Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 108:16723\u201316728","journal-title":"Proc Natl Acad Sci USA"},{"key":"2072_CR14","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","volume":"61","author":"RR Ji","year":"2012","unstructured":"Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, Jackson JR, Shahabi V (2012) An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61:1019\u20131031","journal-title":"Cancer Immunol Immunother"},{"key":"2072_CR15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1479-5876-9-204","volume":"9","author":"O Hamid","year":"2011","unstructured":"Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, G\u00f3mez H, Bastholt L, Chasalow SD, Berman D (2011) A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9:204","journal-title":"J Transl Med"},{"key":"2072_CR16","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1158\/1078-0432.CCR-11-0407","volume":"17","author":"RR Huang","year":"2011","unstructured":"Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy JA, Cochran AJ, Ribas A (2011) CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res 17:4101\u20134109","journal-title":"Clin Cancer Res"},{"key":"2072_CR17","doi-asserted-by":"crossref","first-page":"e27817","DOI":"10.4161\/onci.27817","volume":"3","author":"S Champiat","year":"2014","unstructured":"Champiat S, Fert\u00e9 C, Lebel-Binay S, Eggermont A, Soria JC (2014) Exomics and immunogenics. Bridging mutational load and immune checkpoints efficacy. OncoImmunology 3:e27817","journal-title":"OncoImmunology"},{"key":"2072_CR18","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189\u20132199","journal-title":"N Engl J Med"},{"key":"2072_CR19","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, Maio M, Binder M, Bonsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420","journal-title":"Clin Cancer Res"},{"key":"2072_CR20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1078-0432.CCR-1161-03","volume":"10","author":"A Lad\u00e1nyi","year":"2004","unstructured":"Lad\u00e1nyi A, Somlai B, Gilde K, Fej\u00f6s Z, Gaudi I, T\u00edm\u00e1r J (2004) T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 10:521\u2013530","journal-title":"Clin Cancer Res"},{"key":"2072_CR21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12253-010-9254-x","volume":"16","author":"A Lad\u00e1nyi","year":"2010","unstructured":"Lad\u00e1nyi A, Mohos A, Somlai B, Liszkay G, Gilde K, Fej\u0151s Z, Gaudi I, T\u00edm\u00e1r J (2010) FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma. Pathol Oncol Res 16:303\u2013309","journal-title":"Pathol Oncol Res"},{"key":"2072_CR22","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00262-011-1071-x","volume":"60","author":"A Lad\u00e1nyi","year":"2011","unstructured":"Lad\u00e1nyi A, Kiss J, Mohos A, Somlai B, Liszkay G, Gilde K, Fej\u0151s Z, Gaudi I, Dobos J, T\u00edm\u00e1r J (2011) Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immunother 60:1729\u20131738","journal-title":"Cancer Immunol Immunother"},{"key":"2072_CR23","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","volume":"72","author":"G Erdag","year":"2012","unstructured":"Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, Patterson JW, Slingluff CL Jr (2012) Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 72:1070\u20131080","journal-title":"Cancer Res"},{"key":"2072_CR24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.coi.2013.02.009","volume":"25","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S (2013) Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 25:268\u2013276","journal-title":"Curr Opin Immunol"},{"key":"2072_CR25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563\u2013567","journal-title":"Nature"},{"key":"2072_CR26","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A, for the POPLAR Study Group (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicenter, open-label, phase 2 randomised controlled trial. Lancet 387:1837\u20131846","journal-title":"Lancet"},{"key":"2072_CR27","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568\u2013571","journal-title":"Nature"},{"key":"2072_CR28","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JB, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064\u20135074","journal-title":"Clin Cancer Res"},{"key":"2072_CR29","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF (2013) Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Transl Med 5:200ra116","journal-title":"Sci Transl Med"},{"key":"2072_CR30","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1084\/jem.20130573","volume":"210","author":"Y Bulliard","year":"2013","unstructured":"Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL (2013) Activating Fc \u03b3 receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 210:1685\u20131693","journal-title":"J Exp Med"},{"key":"2072_CR31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","volume":"1","author":"MJ Selby","year":"2013","unstructured":"Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ (2013) Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1:32\u201342","journal-title":"Cancer Immunol Res"},{"key":"2072_CR32","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210:1695\u20131710","journal-title":"J Exp Med"},{"key":"2072_CR33","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1073\/pnas.1417320112","volume":"112","author":"E Romano","year":"2015","unstructured":"Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero P, Speiser DE (2015) Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci 112:6140\u20136145","journal-title":"Proc Natl Acad Sci"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-017-2072-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2072-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2072-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T09:17:16Z","timestamp":1589793436000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-017-2072-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,7]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["2072"],"URL":"https:\/\/doi.org\/10.1007\/s00262-017-2072-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,7]]}}}